Group 2 Innate Lymphoid Cells in Allergic Rhinitis
Shuang Wang,Xuexia Liu,Xinhua Lin,Xiaojing Lv,Hua Zhang
DOI: https://doi.org/10.2147/jir.s485128
IF: 4.5
2024-11-10
Journal of Inflammation Research
Abstract:Shuang Wang, 1– 4, &ast Xuexia Liu, 5 Xinhua Lin, 1– 4, &ast Xiaojing Lv, 2– 4 Hua Zhang 2– 4 1 School of Clinical Medicine, Shandong Second Medical University, Weifang, People's Republic of China; 2 Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, People's Republic of China; 3 Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, People's Republic of China; 4 Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, People's Republic of China; 5 Shandong Stem Cell Engineering Technology Research Center, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xuexia Liu; Hua Zhang, Department of Otorhinolaryngology & Head and Neck Surgery, Yuhuangding Hospital Affiliated to Qingdao University, No. 20 East, Yuhuangding Road, Yantai, Shandong, 264000, People's Republic of China, Tel +86-15154502782, Email ; Allergic rhinitis (AR), which presents symptoms like sneezing and a runny nose, is categorized as an upper respiratory condition of type 2. Recent progress in comprehending AR has revealed the significant role played by type 2 cytokines, specifically interleukin (IL)-13, IL-4, and IL-5. These cytokines are released by helper T cells 2 (Th2) and innate lymphoid cells (ILC2s). ILC2s have the ability to interact with various immune cells and are essential in promoting both type 2 immune response and tissue repair, contributing to normal homeostatic functions within the body. This article presents a summary of the latest advancements in comprehending the activity of ILC2s, with particular emphasis on their potential role involvement in AR. It explores how they collaborate with Th2 cells to exacerbate nasal inflammation and interact with regulatory T cells (Tregs) to counteract the suppressive role mediated by Tregs during allergic inflammation. The significance of ILC2s in allergen-specific therapy is highlighted. A comprehensive understanding of ILC2s biology establishes a robust foundation for unraveling the pathogenesis of AR and devising innovative therapeutic approaches for its management. Keywords: allergic rhinitis, group 2 innate lymphoid cells, cytokines, Treg cells, Th2 cells The characteristic indications of allergic rhinitis consist of sneezing, nasal blockage, itching in the nose and a runny nose. These symptoms are activated by breathing in allergens and managed by immunoglobulin E (IgE), which results in an increase of Th2 cells and type 2 cytokines within the nasal mucosa. AR is a prevalent global allergic disease. 1–3 Group 2 innate lymphoid cells (ILC2s) play a crucial role in the establishment and preservation of immunity, alongside conventional Th2 cells. This diverse group of innate immune cells is indispensable for immune system functionality. 4,5 ILCs predominantly reside in mucosal tissues and exhibit rapid responsiveness towards environmental pathogens and damage. Upon being activated, ILCs release substantial quantities of cytokines, attract additional immune and inflammatory cells, trigger the activation of adaptive immune cells, and facilitate physiological as well as pathological responses. 6,7 There are three primary categories of ILCs that can be distinguished: ILC1s, ILC2s, and ILC3s. 5,7,8 The activity of ILC1s is regulated by a specific transcription factor known as T-box transcription factor. This regulation leads to the release of IFN-a and TNF-y when IL-1, IL-15, and IL-11 are activated. 6,7 GATA-binding protein 3 (GATA3) plays a crucial role in controlling the function of ILC2s, 9,10 resulting in the secretion of cytokines similar to Th2 cells such as IL-13 and IL-5. Activation of either IL-23 or IL-1β triggers the release of both IL-22 and IL-17 from ILC3s. 11–13 Numerous studies have indicated an increase in ILC2s among individuals with AR as well as mouse models. 14–16 These findings suggest that ILC2s may play a positive role in the development of AR.Hence, it is crucial to enhance our understanding of the involvement of ILC2s in the development of AR in order to devise more effective approaches for its management. Consequently, targeted activation of ILC2s may prove to be an important approach for treating AR. In this review, we provide a concise overview of the pathogenesis involved in ILC2s-induced AR, along with an examination of existing and prospective therapeutic strategies (Table 1). Table 1 Clinical and Bas -Abstract Truncated-
immunology